1. Home
  2. ADXN vs SNGX Comparison

ADXN vs SNGX Comparison

Compare ADXN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

HOLD

Current Price

$8.10

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.65

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADXN
SNGX
Founded
2002
1987
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
13.8M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
ADXN
SNGX
Price
$8.10
$1.65
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
8.1K
286.9K
Earning Date
12-04-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$198,824.00
N/A
Revenue This Year
$86.57
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.51
$1.09
52 Week High
$12.05
$6.23

Technical Indicators

Market Signals
Indicator
ADXN
SNGX
Relative Strength Index (RSI) 47.77 59.15
Support Level $7.12 $1.55
Resistance Level $8.49 $1.60
Average True Range (ATR) 0.58 0.12
MACD 0.01 0.03
Stochastic Oscillator 52.40 86.96

Price Performance

Historical Comparison
ADXN
SNGX

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: